MAPP BIOPHARMACEUTICAL, INC.

MAPP BIOPHARMACEUTICAL, INC. specializes in the research, development, and production of advanced biotechnological therapeutics for infectious disease countermeasures, with deep expertise in monoclonal antibody platforms, immunotherapies, and preclinical-to-clinical transition of biologics. The company designs and manufactures targeted antibody-based interventions against high-consequence pathogens such as Ebola, Sudan, and Marburg viruses, leveraging proprietary expression systems and clinical trial frameworks to accelerate medical countermeasure readiness. Their technical capabilities span recombinant protein development, in vitro diagnostic substance manufacturing, and bioassay validation, with a strong focus on scalable GMP-compatible processes for rapid deployment in outbreak scenarios. A key differentiator is their end-to-end capability in transitioning research-stage candidates into clinically viable therapeutics under federal emergency preparedness mandates. The company maintains a consistent and long-standing relationship with the Department of Health and Human Services, delivering critical biodefense and pandemic preparedness solutions through sustained R&D contracts focused on therapeutic development, clinical protocol updates, and expanded access protocols. They also support the Department of Defense with specialized biopharmaceutical manufacturing and laboratory testing services, particularly in cell line development and diagnostic reagent production, indicating a dual-use focus aligned with national security and public health priorities. MAPP’s primary industry focus lies in biotechnology research and development (NAICS 541714), where they apply cutting-edge molecular biology and immunology to create novel biotherapeutics. Secondary work in diagnostic manufacturing (325413) and testing laboratories (541380) reinforces their position as a vertically integrated biopharma contractor capable of advancing candidates from discovery through regulatory-ready production. As a small business structured as a 2L entity based in San Diego, California, MAPP operates with agility in the federal biodefense market. While currently holding no formal government certifications, their sustained performance on high-stakes HHS and DoD contracts demonstrates proven reliability in mission-critical biopharmaceutical development under stringent regulatory and timeline constraints.